Neuroectodermal Tumors, Primitive
15 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
Neuroectodermal Tumors, Primitive| Treatment and condition | Where it stands | Trials |
|---|
| 68-Gallium DOTATATE for neuroectodermal tumors, primitive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Autologous hALK.CAR T cells for neuroblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous NK cell plus GD2 antibody for neuroblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Blood Sample + Cerebrospinal Fluid (CSF) Sample + Chemotherapy Drug, Cancer - Physician's Choice + Non-Investigational Surgical Resection + Radiotherapy (RT) + Tumor Tissue Sample + Temozolomide for neuroectodermal tumors, primitive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy + MAPK inhibitors + ARSENIC TRIOXIDE for neuroblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Educational and Media Intervention for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Eflornithine for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irradiation + Surgical resection + PEGFILGRASTIM + Vincristine + ETOPOSIDE + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Bone Marrow Aspiration + Bone Marrow Biopsy + Clinical Observation + Computed Tomography + Ultrasound + ETOPOSIDE + Doxorubicin hydrochloride + Cyclophosphamide + Carboplatin for ganglioneuroblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Clinical Observation + Computed Tomography + Ultrasound for ganglioneuroblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Laboratory Biomarker Analysis + Radiation Therapy + Vincristine + Lomustine + Cyclophosphamide + CISPLATIN + Vincristine Sulfate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Metformin hydrochloride for medulloblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ommaya/VPS + Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo + Metformin for medulloblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|